Please login to the form below

Not currently logged in
Email:
Password:

H1N1 vaccines move step closer

GSK's first clinical trial for its adjuvanted pandemic vaccine is underway. Meanwhile, Sanofi Pasteur has submitted a supplemental application for licensing of its H1N1 2009 monovalent vaccine

GlaxoSmithKline's (GSK) first clinical trial for its adjuvanted pandemic vaccine is underway. Meanwhile, Sanofi Pasteur has submitted a supplemental application for licensing of its A(H1N1) 2009 monovalent vaccine to the US Food and Drug Administration (FDA). 

Enrolment for the GSK study has been completed and the clinical trial, being conducted in Germany, will assess the use of the vaccine in healthy adults. Initial data is expected to be available for sharing with regulatory authorities in September. Further trials of the pandemic (H1N1) 2009 adjunvanted vaccine covering infants, children, adults and the elderly will commence over the coming weeks across Europe, Canada and the US.

Sanofi Pasteur's supplemental application follows recent recommendations by the FDA to evaluate the influenza A (H1N1) 2009 monovalent vaccines using the same regulatory process by which it approves new viral strains contained in the annual seasonal influenza vaccines. The supplemental application is expected to expedite the vaccine's licensing process. 

17th August 2009

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Porterhouse Medical Group

The Porterhouse Medical Group provides powerful, insight-driven, healthcare communication services to the pharmaceutical industry across the globe, with a focus...

Latest intelligence

Personalised medicine: driving a need for greater diversity in clinical trials
Kate Shaw, Innovative Trials' Founder & CEO, investigates one of the biggest challenges facing clinical research today....
Congresses and conferences
Superstar congresses and conferences will stay centre stage but now share the limelight with virtual and hybrid events
With the pandemic having dimmed the lights on pharma conferences, their virtual and hybrid replacements have grasped the opportunity and are here to stay...
Cervical Cancer Prevention Month
In this first 2022 blog, the Innovative Trials' Equality & Diversity committee will be looking at raising awareness around Cervical Cancer...